Global, regional, and national liver cancer attributable to smoking and alcohol use burden, 1990-2021: analysis for the global burden of disease 2021 study

1990-2021年全球、区域和国家层面由吸烟和饮酒造成的肝癌负担:2021年全球疾病负担研究分析

阅读:1

Abstract

BACKGROUND: Liver cancer poses a significant global health challenge. Smoking and alcohol consumption are major risk factors for liver cancer. METHODS: We analyzed data from the Global Burden of Disease (GBD) Study 2021. First, numbers and age-standardized rates of deaths and disability-adjusted life years (DALYs) were assessed globally and by sub-types in 2021. Furthermore, the temporal trend of the disease burden was explored by the linear regression model from 1990 to 2019. Based on the EAPC values, we conducted a hierarchical cluster analysis to categorize the 54 GBD regions into four groups. To explore potential associations between the EAPCs and socioeconomic factors, we employed the Spearman correlation analysis to evaluate the correlation between EAPCs and ASRs, as well as Human Development Index (HDI) scores. Finally, frontier analysis was used to visually demonstrate the potential for burden reduction in each country or region based on their development levels. All analyses were conducted using R software. RESULTS: From 1990 to 2021, the burden of liver cancer attributed to alcohol consumption increased significantly, whereas age-standardized rates (ASRs) remained relatively stable compared to those associated with smoking.In 2021, the number of deaths and disability-adjusted life years (DALYs) due to smoking-related liver cancer were 53,054 (95% uncertainty interval [UI]: 18,268–88,111) and 1,482,896 (95% UI: 505,000–2,478,906), respectively. The corresponding age-standardized rates (ASRs) were 0.61 per 100,000 population (95% UI: 0.21–1.01) for mortality and 16.9 per 100,000 (95% UI: 5.76–28.26) for DALYs. The estimated annual percentage changes (EAPCs) for these ASRs were − 0.84 (95% confidence interval [CI]: -0.96 to -0.73) for mortality and − 1.12 (95% CI: -1.24 to -1.01) for DALYs.Conversely, in 2021, deaths and DALYs attributable to alcohol-related liver cancer totaled 93,807 (95% UI: 77,476–113,542) and 2,385,090 (95% UI: 1,949,109–2,911,783), respectively. The corresponding ASRs were 1.08 per 100,000 (95% UI: 0.89–1.30) for mortality and 27.2 per 100,000 (95% UI: 22.25–33.1) for DALYs. The EAPCs were 0.26 (95% CI: 0.19–0.32) for mortality and 0.04 (95% CI: -0.03 to 0.10) for DALYs. Males, middle-aged, and older adults were high-risk populations, and middle socio-demographic index (SDI) regions were high-risk areas. The Western Pacific had the highest ASDR for smoking-related liver cancer, while East Asia recorded the highest ASDAR. For alcohol-related liver cancer, the Commonwealth High-Income region exhibited the highest ASDR, whereas Australasia had the highest ASDAR. Andean Latin America had the lowest ASRs for both smoking- and alcohol-related liver cancer. Notably, Mongolia had the highest ASRs for liver cancer attributed to both smoking and alcohol consumption, with values hundreds of times greater than those in the country with the lowest burden, Morocco. CONCLUSION: Although the ASRs of smoking-related liver cancer have continued to decline, the absolute number of cases remains high, and the burden of alcohol-related liver cancer continues to rise. Consequently, the overall disease burden associated with smoking and alcohol consumption remains significant, highlighting the urgent need for more effective risk factor control strategies. Furthermore, the establishment of accurate and efficient screening systems, as well as specialized cancer treatment centers, is imperative—particularly for high-risk populations, such as middle-aged and elderly men, and for high-risk regions classified as High and Middle SDI areas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-025-23184-3.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。